John Christophel, MD
Otolaryngology · Charlottesville, VANPI 1417169111
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,031 of the $7,268 with a category attached, or 69.2%. 31 manufacturers reported payments, led by Synthes GmbH at 32.2% of the total. Reporting peaked in 2019 at $2,343 and has fallen 51.3% since, to $1,141 in 2025.
Across 198 payments — averaging $36.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Synthes GmbH$2K
- Biocryst US Sales Co., LLC$803
- Regeneron Healthcare Solutions, Inc.$781
- Aerin Medical Inc.$665
- Sanofi$521
- CSL Behring$383
- plus $2K from 25 others
Across 1 payment — averaging $2500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Aerin Medical Inc.$3K
What the payments were for
- Speaking & faculty fees$1,50021%
- Travel & lodging$6799%
- Food & beverage$5,03169%
- Education$581%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Synthes GmbH | 3 | $2,343 |
| Biocryst US Sales Co., LLC | 36 | $803 |
| Regeneron Healthcare Solutions, Inc. | 37 | $781 |
| Aerin Medical Inc. | 4 | $665 |
| Sanofi | 21 | $521 |
| CSL Behring | 22 | $383 |
| GSK | 19 | $380 |
| Optinose US, Inc. | 10 | $260 |
| Genentech USA, Inc. | 6 | $240 |
| Stryker | 2 | $139 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $117 |
| Pharming Healthcare, Inc. | 4 | $78 |
| Medtronic | 4 | $69 |
| Hikma Pharmaceuticals USA | 3 | $51 |
| Pfizer | 2 | $45 |
| Alk-abello, Inc | 3 | $42 |
| Lifenet Health | 1 | $38 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $37 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $37 |
| Smith+Nephew | 1 | $33 |
| Kerecis Limited | 1 | $28 |
| Aimmune Therapeutics, Inc. | 1 | $23 |
| Kaleo, Inc. | 1 | $21 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $21 |
| Novartis | 1 | $20 |
| AstraZeneca | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Octapharma USA, Inc. | 1 | $17 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
| Cycle Pharmaceuticals Inc | 1 | $16 |
| Phathom Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVAER STYLUS$505
- RHINAER STYLUS$505
- Xhance$136
- XOLAIR$125
- NUCALA$106
How this compares
$7,268 in reported general payments places this provider in the 85th percentile of 241 otolaryngology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 24 | $82,848 |
| Ipratropium Bromide | 100 | $2,578 |
| Epinephrine | 17 | $2,430 |
| Azelastine Hcl | 48 | $1,404 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 15 | $1,210 |
| Fluticasone Propionate | 49 | $620 |
| Triamcinolone Acetonide | 27 | $616 |
| Omeprazole | 74 | $574 |
| Montelukast Sodium | 52 | $439 |
| Cephalexin | 54 | $269 |
| Mupirocin | 25 | $131 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 13 | $113 |
| Doxycycline Hyclate | 13 | $98 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 14 | $77 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $51 | $2,43017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 241 otolaryngology providers in Virginia.
Other otolaryngology in Charlottesville
- Spencer PayneCharlottesville$45K
- Jose MattosCharlottesville$24K
- Samuel OyerCharlottesville$9K
- Jonathan GarneauCharlottesville$8K
- Eric DowlingCharlottesville$7K
- David ShonkaCharlottesville$7K
- Nicole FowlerCharlottesville$7K
- Christine MatthewsCharlottesville$5K
- Katherine FedderCharlottesville$4K
- Adam Thompson-HarveyCharlottesville$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.